With deep ties to China, Vivace exits stealth mode with a lead cancer program, platform and $40M
It’s not unusual for investors to quietly seed a stealth biotech long enough to see if they’re on to something, then debut the company with …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
